Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

We recently published a list of Top 10 Insider Sales Last Month. In this article, we are going to take a look at where Tempus ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

Linh H. Le is an accomplished finance and accounting executive with extensive knowledge and expertise that he has implemented ...

Other Strategic Acquisitions and Partnerships to Accelerate Growth The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus AI’s genomics capabilities by adding ...

Completed the acquisition of Ambry Genetics on February 3, 2025. Announced the national launch of the Company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx which was granted ADLT ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics (“Ambry”), which closed on February 3, 2025. Combined with $260 million of capital provided in ...